You're reading the brief from Sun, Oct 4.Back to the latest brief
Sun, Oct 45 items
0 of 5 readTop items today: a large randomized trial finds diet drinks match water for long-term weight loss, while small trials hint that high-dose vitamin B3 and a vitamin D analog may aid treatment of brain and pancreatic cancers.
Two-year trial: diet drinks match water for weight loss
A two-year randomized trial of 493 adults with overweight or obesity found those drinking beverages with aspartame, acesulfame-K or sucralose lost weight and reduced waist size similarly to water drinkers.
Why it mattersProvides randomized evidence for replacing sugary drinks with diet versions long term, informing clinical and public-health advice.
High-dose vitamin B3 shows early promise in glioblastoma
In a small trial, adding high-dose vitamin B3 to standard glioblastoma treatment left 82% of patients progression-free at six months; researchers suggest niacin may revive immune cells suppressed by the cancer, but larger studies are needed.
Why it mattersGlioblastoma is among the deadliest brain cancers, so any survival signal matters, though results remain preliminary.
Vitamin D analog may breach pancreatic cancer's defenses
A small clinical trial found a vitamin D analog may break down pancreatic cancer's protective defenses, making tumors more vulnerable to chemotherapy and immune attack, with encouraging responses especially in tumors high in vitamin D receptor.
Why it mattersPancreatic cancer has few treatment options; if confirmed, this mechanism could open a new route for combination therapy.
Weekly cisplatin fails to cut serious side effects in head and neck cancer
The NRG-HN009 trial found weekly low-dose cisplatin with radiation did not reduce serious side effects versus the every-three-weeks high-dose regimen in p16-negative locally advanced head and neck cancer; randomized evidence comparing the two had been limited.
Why it mattersDirectly challenges the common clinical assumption that weekly dosing is less toxic, potentially affecting chemoradiation choices.
Parasite mitochondria map reveals dozens of drug targets
A four-year effort mapped all mitochondrial proteins of parasites causing sleeping sickness, giardiasis, leishmaniasis and babesiosis—diseases affecting nearly a billion people yearly—revealing dozens of potential new drug targets.
Why it mattersThese neglected tropical diseases long lack new drugs; the target map could accelerate development.